Back

The cardiovascular-kidney-liver-metabolic (CKLM) risk spectrum: synergistic mortality from liver fibrosis and cardiometabolic disease

29 August 2026 (08:15 - 08:25)
Organised by: Logo
Congress Presentation Part of: Secondary prevention after myocardial infarction Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Shenghao Zuo

Xi'an (China)

5 More presentations in this session

Presentation thumbnail
Impact of coronary computed tomography angiography image visualisation on low-density lipoprotein cholesterol reduction in non-obstructive coronary artery disease: a multicentre randomised trial
Doctor A. Kulasingam (Aarhus, DK)
Abstract Slides
Presentation thumbnail
Systolic blood pressure variability and effect of finerenone treatment in patients with chronic kidney disease and type 2 diabetes: a FIDELITY analysis
Doctor S. Rajagopalan (Cleveland, US)
Abstract Slides
Presentation thumbnail
Attainment of secondary prevention goals after myocardial infarction in foreign-born versus native-born patients: nationwide data from SWEDEHEART
Doctor S. Zwackman (Linkoping, SE)
Abstract Slides
Presentation thumbnail
Temporal trends and clinical predictors of GLP-1 receptor agonist and SGLT2 inhibitor use after myocardial infarction among patients with type 2 diabetes
Associate Professor G. Batra (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Cross-physiological and fitness-adjusted assessment of rate–pressure product for residual mortality risk stratification in acute coronary syndrome
Mr H. Cui (Harbin, CN)
Abstract Slides

Access the full session

Session thumbnail
Secondary prevention after myocardial infarction
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular-kidney-metabolic syndrome and association with mortality in the UK Biobank prospective cohort study
1 September 2025
thumbnail
Congress Presentation
The product of bilirubin and trigliseride is the most significant predictor of severe FIB-4 index of liver disease in cardiac patients
30 August 2025
thumbnail
Congress Presentation
Prognostic role of combined hepatorenal dysfunction and malnutrition in patients undergoing valvular heart surgery
1 July 2021
thumbnail
Congress Presentation
Liver steatosis, metabolically healthy obesity and ten-year cardiovascular disease risk: results from a population based cohort study.
28 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources